Polpharma Biologics has entered a global licensing agreement with Fresenius Kabi for the commercialization of PB016, a proposed vedolizumab biosimilar, aimed at improving access to treatment for chronic inflammatory diseases.
Target Information
Polpharma Biologics S.A. is an international biotechnology firm headquartered in Gdańsk, Poland. The company specializes in the development and manufacturing of biosimilar medicines, leveraging advanced platform technologies and patented solutions. Polpharma Biologics focuses on creating affordable biosimilars that address critical therapeutic areas, such as chronic inflammatory diseases.
The company's existing expertise includes successful launches of multiple biosimilars in collaboration with major pharmaceutical partners. With facilities in both the Netherlands and Poland, Polpharma Biologics possesses a comprehensive infrastructure for the entire drug development process, from cell line development to commercial-scale production.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The biosimilars market in Europe is experiencing significant growth, primarily driven by increasing demand for cost-effective alternatives to biologic therapies. Factors such as rising healthcare costs and the growing prevalence of chronic diseases, lik
Similar Deals
Boston Scientific → Nalu Medical
2026
Barça Innovation Hub → Omniscope
2025
Fresenius Kabi
invested in
Polpharma Biologics
in
in a Strategic Partnership deal